CR Sanjiu(SZ:000999) Xin Lang Cai Jing·2025-04-30 01:29Core Insights - The company reported a total revenue of 6.854 billion yuan for Q1 2025, ranking third among peers, which represents a decrease of 440 million yuan or 6.04% year-on-year [1] - The net profit attributable to shareholders was 1.270 billion yuan, also ranking third among peers, showing a decline of 93.75 million yuan or 6.87% year-on-year [1] - The net cash inflow from operating activities was 980 million yuan, ranking first among peers, with an increase of 193 million yuan or 24.57% year-on-year, marking two consecutive years of growth [1] Financial Ratios - The latest debt-to-asset ratio is 38.91%, ranking 51st among peers, which is an increase of 1.92 percentage points from the previous quarter and 1.28 percentage points from the same period last year [3] - The latest gross profit margin is 53.28%, ranking 37th among peers, with an increase of 1.42 percentage points from the previous quarter but a decrease of 0.14 percentage points year-on-year [3] - The latest return on equity (ROE) is 6.00%, ranking 5th among peers, which is a decrease of 0.71 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 1.00 yuan, ranking 4th among peers, which is a decrease of 0.07 yuan or 6.54% year-on-year [3] - The total asset turnover ratio is 0.14 times, ranking 23rd among peers, showing a decrease of 0.04 times or 21.88% year-on-year [3] - The inventory turnover ratio is 0.55 times, ranking 34th among peers, with a decrease of 0.12 times or 18.29% year-on-year [3] Shareholder Structure - The number of shareholders is 62,200, with the top ten shareholders holding 914 million shares, accounting for 71.14% of the total share capital [3] - The largest shareholder is China Resources Pharmaceutical Group Limited, holding 63% of the shares [3]